Cargando…

Meta-analysis of clinical trials comparing the efficacy and safety of liposomal cisplatin versus conventional nonliposomal cisplatin in nonsmall cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)

BACKGROUND: While liposomal cisplatin has shown enhanced drug tolerability and higher targeting property as compared with the conventional cisplatin, the doubt remains whether lipoplatin could improve its anticancer efficacy. What's more, there is still no systematic evaluation of the safety pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Bei, Zeng, Min, Zeng, Jiawei, Feng, Jiafu, Yu, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257614/ https://www.ncbi.nlm.nih.gov/pubmed/30431590 http://dx.doi.org/10.1097/MD.0000000000013169

Ejemplares similares

Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
por: Rades, Dirk, et al.
Publicado: (2023)

A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN)
por: Guan, Jian, et al.
Publicado: (2016)

Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
por: Katori, H, et al.
Publicado: (2004)

EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
por: Sattler, Martin, et al.
Publicado: (2008)

Analysis of chemokine and chemokine receptor expression in squamous cell carcinoma of the head and neck (SCCHN) cell lines
por: Wolff, Hendrik A., et al.
Publicado: (2010)

Patient Complications after Interscalene Block: A Retrospective Comparison of Liposomal Bupivacaine to Nonliposomal Bupivacaine
por: Hutchins, Jacob L., et al.
Publicado: (2020)

New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)
por: Agulnik, Mark
Publicado: (2012)

PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance
por: Liu, Minghui, et al.
Publicado: (2021)

Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer
por: Stathopoulos, G. P., et al.
Publicado: (2011)

Decitabine Rescues Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma
por: Viet, Chi T., et al.
Publicado: (2014)

First-Line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients
por: Li, Ying, et al.
Publicado: (2014)

Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck.
por: KjellÃ©n, E., et al.
Publicado: (1989)

Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas
por: Griso, Ana Belén, et al.
Publicado: (2022)

Incidence trends of squamous cell carcinoma of the head and neck (SCCHN) in the aging population––A SEER‐based analysis from 2000 to 2016
por: Taylor, Melissa A., et al.
Publicado: (2021)

Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance
por: Liu, Shutong, et al.
Publicado: (2017)

MicroRNA-21 induces cisplatin resistance in head and neck squamous cell carcinoma
por: Sheng, Shuyan, et al.
Publicado: (2022)

Eligibility criteria to cisplatin in head and neck squamous cell carcinoma: Egyptian expert opinion
por: Abdulla, Mohamed, et al.
Publicado: (2023)

Transcriptomic and Proteomic Profiles for Elucidating Cisplatin Resistance in Head-and-Neck Squamous Cell Carcinoma
por: Garcia-Mayea, Yoelsis, et al.
Publicado: (2022)

Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
por: Jensen, Alexandra D, et al.
Publicado: (2011)

The checkpointkinase 2 (CHK2) 1100delC germ line mutation is not associated with the development of squamous cell carcinoma of the head and neck (SCCHN)
por: Scheckenbach, Kathrin, et al.
Publicado: (2010)

Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experience
por: Jensen, Alexandra D, et al.
Publicado: (2010)

Real-world study of the impact of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) on quality of life and productivity in Europe
por: Singh, Prianka, et al.
Publicado: (2021)

Methotrexate plus or minus cetuximab as first‐line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib‐randomized phase II study Commence
por: Ham, Janneke C., et al.
Publicado: (2020)

Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells
por: Basak, Saroj K., et al.
Publicado: (2015)

Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma
por: Fayette, Jérôme, et al.
Publicado: (2015)

DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells
por: Martens-de Kemp, Sanne R., et al.
Publicado: (2013)

Feasibility of Cisplatin/5-Fluorouracil and Panitumumab in Japanese Patients with Squamous Cell Carcinoma of the Head and Neck
por: Tahara, Makoto, et al.
Publicado: (2014)

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma
por: Jacinto, Alexandre Arthur, et al.
Publicado: (2018)

Inhaled Cisplatin for NSCLC: Facts and Results
por: Kosmidis, Christoforos, et al.
Publicado: (2019)

Cisplatin effect on head and neck squamous cell carcinoma cells is modulated by ERK1/2 protein kinases
por: Bostan, Marinela, et al.
Publicado: (2019)

Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective Review
por: Peddi, Prakash, et al.
Publicado: (2015)

Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma
por: Longton, Eleonore, et al.
Publicado: (2018)

Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway
por: Yang, Zejia, et al.
Publicado: (2019)

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
por: Kim, Moon Jin, et al.
Publicado: (2019)

Concurrent Chemoradiotherapy With Weekly Low-Dose Cisplatin for Japanese Patients With Head and Neck Squamous Cell Carcinoma
por: Shinohara, Shogo, et al.
Publicado: (2021)

Comparing high‐dose cisplatin with cisplatin‐based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC)
por: Furqan, Muhammad, et al.
Publicado: (2019)

Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial
por: Wiegand, Susanne, et al.
Publicado: (2023)

In vitro evaluation of photon and carbon ion radiotherapy in combination with cisplatin in head and neck squamous cell carcinoma cell lines
por: Fang, Xumeng, et al.
Publicado: (2023)

S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy in Chinese patients with nonsmall-cell lung cancer: A multicentre randomized controlled trial
por: Feng, Junfei, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_05ai8iu3qn81ffsgbfq8odjldi